← Back to Search

PD-L1 Inhibitor

MEDI4736 for Squamous Cell Carcinoma

Phase 2
Waitlist Available
Led By Dan Paul Zandberg, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR

Eligible Conditions
  • Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Objective Response Rate (ORR)
Secondary study objectives
Best Objective Response
Disease Control at 6 Months
Duration of Response
+5 more

Side effects data

From 2023 Phase 3 trial • 713 Patients • NCT02125461
36%
Cough
24%
Fatigue
22%
Dyspnoea
18%
Diarrhoea
17%
Arthralgia
17%
Radiation pneumonitis
15%
Pyrexia
15%
Decreased appetite
14%
Nausea
13%
Pruritus
13%
Rash
12%
Upper respiratory tract infection
12%
Constipation
11%
Asthenia
11%
Hypothyroidism
11%
Headache
11%
Back pain
10%
Productive cough
10%
Pneumonia
9%
Pneumonitis
9%
Nasopharyngitis
9%
Insomnia
8%
Musculoskeletal pain
8%
Vomiting
8%
Oedema peripheral
8%
Myalgia
8%
Dry skin
7%
Hyperthyroidism
7%
Anaemia
7%
Bronchitis
7%
Dizziness
7%
Non-cardiac chest pain
7%
Pain in extremity
6%
Urinary tract infection
5%
Hypertension
5%
Hypokalaemia
5%
Paraesthesia
5%
Musculoskeletal chest pain
1%
Lung infection
1%
Atrial fibrillation
1%
Myocardial infarction
1%
Cardiac failure congestive
1%
Sepsis
1%
Herpes zoster
1%
Chronic obstructive pulmonary disease
1%
Acute kidney injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
Durvalumab (MEDI4736)
Placebo

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MEDI4736Experimental Treatment1 Intervention
MEDI4736 monotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
FDA approved

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,403 Previous Clinical Trials
289,124,897 Total Patients Enrolled
PRA Health SciencesIndustry Sponsor
94 Previous Clinical Trials
42,432 Total Patients Enrolled
Dan Paul Zandberg, MDPrincipal InvestigatorInternational Coordinating Investigator
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top